Hitachi Chemical Co., Ltd. Developed Novel Molecular Testing System for Personalized Medicine – Novel mRNA Quantitative Assay for Biomarker Discovery and Prediction of Drug Efficacy
11/15/2012 10:05:10 AM
TOKYO--(BUSINESS WIRE)--Hitachi Chemical Co., Ltd. (TOKYO:4217)(Head Office: Tokyo; President and CEO: Kazuyuki Tanaka; Capital: 15.5 billion yen; hereinafter referred to as "Hitachi Chemical"), in the field of life sciences, developed a novel mRNA quantitative assay called "Hem(A)+ System"i. This is a simple, high-throughput, reproducible method, that offers a wide range of applications in clinical biomarker discovery and molecular testing to target personalized medicineii.
comments powered by